Obesity and Metabolic Syndrome

Obesity and Metabolic Syndrome

Obesity and Metabolic Syndrome

On this page

Obesity - Sizing Up & Risks

  • Definition: Excess body fat posing health risk. BMI ($kg/m^2$):
    • WHO: Underweight <18.5; Normal 18.5-24.9; Overweight 25-29.9; Obesity I 30-34.9, II 35-39.9, III ≥40.
    • Asian Indian: Overweight 23-24.9; Obesity ≥25.
  • BMI Formula: $BMI = \text{weight (kg)} / (\text{height (m)})^2$.
  • Etiology: Multifactorial (genetics, lifestyle, endocrine e.g., hypothyroidism, Cushing's).
  • Assessment:
    • BMI.
    • Waist Circumference (WC) (Indian): M >90cm, F >80cm (Central Obesity).
    • Waist-to-Hip Ratio (WHR): ↑Risk M >0.90, F >0.85.

    ⭐ Central obesity (↑ WC) is a better predictor of metabolic risk than BMI alone, especially in Asian populations.

  • Major Complications: T2DM, CVD, HTN, Dyslipidemia, OSA, NAFLD, PCOS, Cancers (e.g., endometrial, breast, colon).

Obesity Management - The Battle Plan

  • 1. Lifestyle Modification (Cornerstone)
    • Diet: Calorie deficit (↓500-750 kcal/day).
    • Exercise: ≥150 min/week moderate-intensity aerobic activity.
    • Behavioral Therapy: CBT, motivational interviewing.
  • 2. Pharmacotherapy
    • Indications: BMI ≥30 or ≥27 with comorbidities.
    • Orlistat: Lipase inhibitor; MOA: ↓fat absorption; S/E: steatorrhea, flatus with discharge.
    • Liraglutide (3mg): GLP-1 agonist; MOA: ↑satiety; S/E: nausea, pancreatitis (rare).
  • 3. Bariatric Surgery (Severe Obesity)
    • Indications: BMI ≥40 or ≥35 with comorbidities.
    • Asian (Indian): BMI >37.5 or >32.5 with comorbidities.
    • Types: Sleeve Gastrectomy (LSG - restrictive), Roux-en-Y Gastric Bypass (LRYGB - restrictive & malabsorptive).
    • Outcomes: Weight loss, T2DM remission. Complications: Dumping syndrome, nutritional deficiencies.

⭐ Liraglutide for obesity (Saxenda, 3.0 mg) is higher dose than for diabetes (Victoza, up to 1.8 mg).

Obesity Management Algorithm for Patients >60 Years

Metabolic Syndrome - The Risky Quintet

Metabolic Syndrome (MetS): a cluster of risk factors significantly ↑ risk of Cardiovascular Disease (CVD) & Type 2 Diabetes (T2DM). Diagnosis: $\ge$3 of 5 criteria (NCEP ATP III/IDF, Indian adaptations):

  • Abdominal Obesity (Waist Circumference):
    • Men: >90 cm (South Asian/Indian)
    • Women: >80 cm (South Asian/Indian)
  • Hypertriglyceridemia: TG $\ge$150 mg/dL or on drug therapy.
  • Low HDL-C:
    • Men: <40 mg/dL or on drug therapy.
    • Women: <50 mg/dL or on drug therapy.
  • Hypertension: BP $\ge$130/85 mmHg or on antihypertensive drug.
  • Impaired Fasting Glucose: FG $\ge$100 mg/dL or on drug therapy for hyperglycemia.

Pathophysiology: Core is Insulin Resistance linked to central obesity. Leads to altered adipokine release (↓adiponectin, ↑leptin resistance) & chronic low-grade inflammation.

⭐ Non-alcoholic fatty liver disease (NAFLD) is often considered the hepatic manifestation of MetS.

MetS Management - Holistic Harmony

Primary goals: ↓ ASCVD risk, prevent T2DM. Cornerstone: Lifestyle modification.

  • Lifestyle First
    • Weight reduction: 5-10% body weight
    • Diet: DASH, Mediterranean
    • Physical activity: ≥150 min/wk moderate
  • Pharmacotherapy (Individual components)
    • Hypertension: ACEi/ARB (often preferred)
    • Dyslipidemia: Statins, Fibrates
    • Hyperglycemia: Metformin
    • High CVD risk: Aspirin

⭐ Weight loss of 5-10% is the primary target of lifestyle modification and significantly improves MetS components.

High‑Yield Points - ⚡ Biggest Takeaways

  • Metabolic Syndrome: ≥3 criteria - Abdominal obesity, ↑ Triglycerides (≥150 mg/dL), ↓ HDL-C (<40 men, <50 women), ↑ BP (≥130/85 mmHg), ↑ Fasting Glucose (≥100 mg/dL).
  • Indian waist cut-offs for abdominal obesity: Men ≥90 cm, Women ≥80 cm.
  • Leptin resistance (satiety hormone) and altered Ghrelin (hunger hormone) contribute to obesity.
  • ↓ Adiponectin (insulin-sensitizing adipokine) in obesity is linked to insulin resistance, a core defect.
  • Orlistat: A pancreatic lipase inhibitor used for weight loss; common side effect is steatorrhea.
  • Bariatric surgery is considered for BMI ≥40 kg/m² or BMI ≥35 kg/m² with significant comorbidities.

Practice Questions: Obesity and Metabolic Syndrome

Test your understanding with these related questions

What is the most appropriate insulin regimen for achieving tight control of blood sugar levels in a 20-year-old male with type 1 diabetes mellitus?

1 of 5

Flashcards: Obesity and Metabolic Syndrome

1/10

In refeeding syndrome, severe _____glycemia is seen after excessive insulin release

TAP TO REVEAL ANSWER

In refeeding syndrome, severe _____glycemia is seen after excessive insulin release

hyper

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial